Document is current

Article History

Received: 16 March 2022

Accepted: 10 October 2022

First Online: 8 November 2022

Declarations

:

: This research trial was approved in 2018 by human research ethics committees of JHFMHN, the Aboriginal Health and Medical Research Council (AH&MRC), and CSNSW (Protocol JHFMHN File No G561/17 & HREC/18/JHFMHN/3) including this economic evaluation. The trial was registered to the Australia New Zealand Clinical Trials Registry (ANZCTR) as trial, ACTRN12618000942257, 4/06/2018. The research was funded by the NSW Ministry of Health. The study adhered to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (Additional FilesInternalRef removed). All methods were carried out in accordance with relevant guidelines and regulations. All trial participants gave voluntary and written and informed consent before the administration of any study procedures.

: Not applicable.

: Camurus AB are supplying the drug with no right of veto of publication or dissemination of results. Results will be disclosed and disseminated at the discretion of the Chief Investigator. Adrian Dunlop, Paul Haber and Nicholas Lintzeris have received funding to their institutions from Braeburn Pharmaceuticals (North American partners of Camurus AB) to support a previous and current community trial of CAM2038. No funds were provided directly to these individuals and none of the investigators or their families hold shares in Camurus or Braeburn pharmaceuticals nor stand to make financial gains through their involvement with Camurus AB.All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.